Almirall SA (ES:ALM)
BME:ALM
Want to see ES:ALM full AI Analyst Report?
Top Page
Almirall
(BME:ALM)
Select Model
Select Model
Rating:60Neutral
Price Target:
€12.00
▼(-6.98% Downside)
Action:Reiterated
Date:05/14/26
The score is supported primarily by improving financial performance (recovery in growth and operating profitability with conservative leverage). It is pulled down by weak technical trend signals (below key moving averages with negative MACD) and a high P/E with only a modest dividend yield, which increases sensitivity to any setback in profitability or cash-flow consistency.
Positive Factors
Revenue & margin recovery
Sustained acceleration in revenue alongside meaningful EBITDA margin expansion indicates that core dermatology products are scaling profitably. This structural improvement supports reinvestment in R&D and commercial expansion, improving long-term cash generation and operational resilience.
Negative Factors
Thin net profitability
A low net margin limits internal cash available for growth and makes earnings more sensitive to input cost rises or pricing/reimbursement pressure. Over the medium term, persistently thin profitability can hinder funding for R&D and commercial scale relative to peers.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & margin recovery
Sustained acceleration in revenue alongside meaningful EBITDA margin expansion indicates that core dermatology products are scaling profitably. This structural improvement supports reinvestment in R&D and commercial expansion, improving long-term cash generation and operational resilience.
Read all positive factors
Almirall (ALM) vs. iShares MSCI Spain ETF (EWP)
Market Cap
€2.43B
Dividend Yield1.22%
Average Volume (3M)106.20K
Price to Earnings (P/E)42.7
Beta (1Y)0.61
Revenue Growth12.41%
EPS Growth342.01%
CountryES
Employees2,026
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.24
Shares Outstanding214,785,200
10 Day Avg. Volume134,753
30 Day Avg. Volume106,204
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.85
Price to Sales (P/S)2.49
P/FCF Ratio20.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€14.10Price Target Upside9.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.39
Revenue Forecast (FY)€1.23B
Almirall Business Overview & Revenue Model
Company Description
Almirall (ALM) is a global pharmaceutical company headquartered in Barcelona, Spain, specializing in the research, development, and commercialization of innovative dermatological products. The company operates primarily in the dermatology and resp...
How the Company Makes Money
Almirall makes money mainly by selling prescription pharmaceutical products, with a strategic focus on medical dermatology. Revenue is generated from (1) product sales in its key markets, where it markets and distributes branded dermatology medici...
Almirall Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.37B | 1.11B | 985.72M | 894.52M | 863.25M | 827.20M |
| Gross Profit | 921.82M | 456.65M | 767.68M | 577.12M | 680.78M | 655.61M |
| EBITDA | 458.22M | 218.90M | 173.80M | 114.33M | 157.01M | 132.34M |
| Net Income | 52.42M | 46.20M | 10.15M | -38.47M | 4.28M | -40.86M |
Balance Sheet | ||||||
| Total Assets | 2.33B | 2.34B | 2.40B | 2.37B | 2.15B | 2.14B |
| Cash, Cash Equivalents and Short-Term Investments | 311.20M | 338.82M | 377.30M | 388.09M | 248.82M | 207.39M |
| Total Debt | 285.40M | 342.86M | 408.81M | 403.25M | 403.88M | 396.11M |
| Total Liabilities | 822.60M | 829.74M | 908.28M | 911.59M | 828.98M | 855.71M |
| Stockholders Equity | 1.51B | 1.49B | 1.49B | 1.46B | 1.32B | 1.29B |
Cash Flow | ||||||
| Free Cash Flow | 192.75M | 134.29M | -664.00K | -65.82M | 38.62M | 162.70M |
| Operating Cash Flow | 280.93M | 169.20M | 160.77M | 93.48M | 155.10M | 233.85M |
| Investing Cash Flow | -208.41M | -132.94M | -140.04M | -122.56M | -68.54M | -57.26M |
| Financing Cash Flow | -86.32M | -75.59M | -31.58M | 168.21M | -45.12M | -134.88M |
Almirall Technical Analysis
Negative
12.90
Price Trends
11.95
Negative
12.37
Negative
12.04
Negative
Market Momentum
-0.27
Positive
27.25
Positive
5.85
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:ALM, the sentiment is Negative. The current price of 12.9 is above the 20-day moving average (MA) of 11.99, above the 50-day MA of 11.95, and above the 200-day MA of 12.04, indicating a bearish trend. The MACD of -0.27 indicates Positive momentum. The RSI at 27.25 is Positive, neither overbought nor oversold. The STOCH value of 5.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ES:ALM.
Almirall Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | €919.52M | 15.29 | 45.95% | 3.31% | 14.90% | 5.07% | |
60 Neutral | €2.43B | 42.68 | 3.53% | 1.22% | 12.41% | 342.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | €1.42B | 14.71 | 18.13% | 3.51% | 23.66% | -28.51% | |
46 Neutral | €221.33M | 16.80 | 2.03% | 1.91% | -2.30% | -52.51% |
* Healthcare Sector Average
ES:ALM
Almirall
11.38
1.06
10.24%
ES:CBAV
Clinica Baviera
55.20
17.84
47.76%
ES:FAE
Faes Farma
4.61
0.49
11.78%
ES:RJF
LABORATORIO REIG JOFRE
2.74
-0.33
-10.75%
Almirall Corporate Events
Almirall Schedules Webcast to Present Q1 2026 Results to Investors
May 12, 2026
Almirall will host a webcast for analysts and institutional investors to present and discuss its financial results for the first quarter of 2026, scheduled for 11 May at 10:00 a.m. CET. The event, which underscores the company’s ongoing inve...
Almirall Shareholders Approve 2025 Accounts, Dividend and Financing Flexibility
May 12, 2026
Almirall’s shareholders approved the company’s individual and consolidated financial statements and management reports for 2025, along with its non-financial and sustainability information, formally endorsing the board’s manageme...
Almirall Opts for Scrip Dividend via Capital Increase from Reserves
May 12, 2026
Almirall has announced details of a scrip dividend approved by its Ordinary General Shareholders’ Meeting held on 8 May 2026, opting to implement the payout via a capital increase charged to reserves from undistributed profits. The company h...
Almirall Refines Board Committees and Advances Scrip Dividend Plan
May 12, 2026
Almirall’s board, meeting after the 8 May 2026 shareholders’ meeting, confirmed a series of governance moves, including the re-election of Eva Abans Iglesias as chair of the Audit and Sustainability Committee and the re-election of Ugo...
Almirall Issues Cautious Q1 2026 Financial and Business Update
May 12, 2026
Almirall has released a presentation of its Q1 2026 financial results and business update, prepared primarily for internal and investor communication purposes. The document emphasizes that the information is summarized, may differ from the authori...
Almirall Sets Timetable for 2026 Scrip Dividend and Bonus Share Issue
May 12, 2026
Almirall has approved a bonus share capital increase to implement a scrip dividend system, allowing shareholders to choose between receiving their dividend in cash, new shares, or a combination of both. The initiative reflects the company’s ...
Almirall Corrects Reference Share Price for Scrip Dividend Capital Increase
May 12, 2026
Almirall has identified an external error in the previously reported weighted average share price used to calculate the terms of its scrip dividend-related bonus share capital increase, correcting the reference price from €10.291 to €1...
Almirall Calls 2026 Shareholders’ Meeting with Governance Changes and Scrip Dividend Plan
Apr 8, 2026
Almirall has convened its Ordinary General Shareholders’ Meeting for 8 May 2026 in Barcelona, with a second-call date set for 9 May if quorum is not reached. Shareholders will be asked to approve the company’s and group’s 2025 fi...
Almirall Updates Board Regulations to Strengthen Corporate Governance Framework
Mar 19, 2026
Almirall’s Board of Directors has approved updated internal regulations that codify the principles guiding the board’s actions, its organizational structure, and the conduct expected from directors and senior managers. The rules are de...
Almirall Schedules Webcast to Present 2025 Financial Results
Feb 24, 2026
Almirall will present and discuss its 2025 financial results in a webcast with analysts and institutional investors on 23 February 2026 at 10:00 a.m. CET. The event, which can be followed live and later via full recording on the company’s we...
Almirall Publishes 2025 Corporate Governance Report in Enhanced Narrative Format
Feb 24, 2026
Almirall has released its 2025 Annual Corporate Governance Report, prepared in a free format authorized by Spain’s securities regulator, the CNMV, while preserving references to the official structure. The report aims to enhance clarity and ...
Almirall’s 2025 Pay Report Highlights Strong Dermatology Growth and Governance Backing
Feb 24, 2026
Almirall reported higher net sales in 2025, driven chiefly by strong performance of its European dermatology portfolio, notably Ebglyss, Ilumetri, and Wynzora, with Ebglyss expanding into major European markets. On the RD front, the Anti-IL1RAP ca...
Almirall Posts Slight Decline in Total Assets as 2025 Balance Sheet Remains Stable
Feb 24, 2026
Almirall reported total assets of €2.56 billion at 31 December 2025, slightly down from €2.59 billion a year earlier, reflecting a modest decrease in its balance sheet size. Non‑current assets declined mainly due to lower investm...
Almirall Issues FY 2025 Update With Strictly Informational Disclaimer
Feb 24, 2026
Almirall released a brief financial results and business update document for fiscal year 2025, dated February 23, 2026, intended solely for use during a company presentation. The company stresses that the material is a summarized Spanish translati...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.